Skip to content

MARKER THERAPEUTICS, INC.: 10-Q/A filed 2016-04-14

What MARKER THERAPEUTICS, INC. reported in its quarterly report amendment filed 2016-04-14 (fiscal Q2 2015): 14 published measures, 33 facts as tagged in accession 0001193125-16-541467.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2016-04-14
Fiscal period
fiscal Q2 2015
Accession
0001193125-16-541467 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MARKER THERAPEUTICS, INC. filings.

Reported measures

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-06-30-68,102,079USD
At 2014-12-31-1,023,636USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-60,216,294USD91
2015-01-01 to 2015-06-30-60,917,018USD181
2014-04-01 to 2014-06-30753,480USD91
2014-01-01 to 2014-06-30-28,953,750USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2015-01-01 to 2015-06-30-1,827,638USD181
2014-01-01 to 2014-06-30-611,442USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2015-01-01 to 2015-06-304,791,014USD181
2014-01-01 to 2014-06-30583,500USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-06-30-160,359,055USD
At 2014-12-31-86,309,731USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-01-01 to 2015-06-30248,561USD181
2014-01-01 to 2014-06-30799,075USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-06-303,247,910USD
At 2014-12-31224,448USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-06-3071,349,989USD
At 2014-12-311,248,084USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-04-01 to 2015-06-30201,157USD91
2015-01-01 to 2015-06-30810,535USD181
2014-04-01 to 2014-06-3022,500USD91
2014-01-01 to 2014-06-3045,000USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-06-3038,038,921shares
At 2014-12-3120,318,815shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-06-3092,218,937USD
At 2014-12-3185,265,776USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2015-01-01 to 2015-06-30-60,917,018USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-30936,887USD91
2015-01-01 to 2015-06-301,355,673USD181
2014-04-01 to 2014-06-30488,427USD91
2014-01-01 to 2014-06-301,687,794USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-01-01 to 2015-06-302,326,014USD181
2014-01-01 to 2014-06-30583,000USD181

Inspect the source

Entity
MARKER THERAPEUTICS, INC. / CIK 0001094038
Captured
2026-09-20T05:22:11.393Z
SEC response SHA-256
11a45295baae8ad4450041d3d51c2454c6531734b6bbb806e124ea5eb0db02da

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001094038.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))